HER2 Levels May Aid In Treatment Selection For Metastatic Breast Cancer

News — By on December 3, 2008 at 7:00 am

Findings published in the December 1, 2008, issue of Clinical Cancer Research , a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit.

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback